RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2024 -- It is with deep sadness that Pappas Capital announces the passing of Dr. Ernest Mario, Senior Venture Partner and one of the founders...
Plexxikon, Wyeth PPAR Deal: Up to $372M In Diabetes Bid (BioWorld Today)
News | 11. 01. 2004
Plexxikon
If there’s anxiety lingering after the FDA’s summer ruling about potential cancer toxicity with peroxisome proliferator-activated receptors (PPARs), you wouldn’t know it from Wyeth – which entered a potential $372 mil- lion deal with Plexxikon Inc. to develop treatments for diabetes and metabolic disorders.
